FilingReader Intelligence
Kangtai Bio receives positive tetanus vaccine trial results
March 4, 2025 at 05:14 AM UTC•By FilingReader AI
Shenzhen Kangtai Biological Products announced that its wholly-owned subsidiary, Beijing Minhai Biotechnology, has received the summary report for the Phase I/III clinical trial of its adsorbed tetanus vaccine. The study results indicate the vaccine demonstrated good safety and immunogenicity in adults.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
News Alerts
Get instant email alerts when Shenzhen Kangtai Biological Products publishes news
Free account required • Unsubscribe anytime